Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Cherevka Holli
   2. Issuer Name and Ticker or Trading Symbol
Ampio Pharmaceuticals, Inc. [AMPE] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Operating Officer
(Last)
(First)
(Middle)
C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200		 3. Date of Earliest Transaction (Month/Day/Year)
10/01/2018
(Street)

ENGLEWOOD, CO 80112		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $ 4.72 10/01/2018   D(1)     45,000   (2) 04/02/2023 Common Stock 45,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 0.75 10/01/2018   A(1)   45,000     (2) 04/02/2023 Common Stock 45,000 $ 0 45,000 D  
Employee Stock Option (Right to Buy) $ 3.43 10/01/2018   D(1)     30,000   (2) 10/06/2024 Common Stock 30,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 0.75 10/01/2018   A(1)   30,000     (2) 10/06/2024 Common Stock 30,000 $ 0 30,000 D  
Employee Stock Option (Right to Buy) $ 1.03 10/01/2018   D(1)     170,000   (2) 07/15/2026 Common Stock 170,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 0.75 10/01/2018   A(1)   170,000     (2) 07/15/2026 Common Stock 170,000 $ 0 170,000 D  
Employee Stock Option (Right to Buy) $ 4.16 10/01/2018   D(1)     35,000   (2) 01/14/2023 Common Stock 35,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 0.75 10/01/2018   A(1)   35,000     (2) 01/14/2023 Common Stock 35,000 $ 0 35,000 D  
Employee Stock Option (Right to Buy) $ 8.62 10/01/2018   D(1)     9,402   (2) 11/08/2023 Common Stock 9,402 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 0.75 10/01/2018   A(1)   9,402     (2) 11/08/2023 Common Stock 9,402 $ 0 9,402 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Cherevka Holli
C/O AMPIO PHARMACEUTICALS, INC.
373 INVERNESS PARKWAY, SUITE 200
ENGLEWOOD, CO 80112		       Chief Operating Officer  

Signatures

 /s/ Holli Cherevka   10/02/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on October 1, 2018 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each "Relevant Option" has been amended to reduce such exercise price to $0.75. There have been no other changes to the terms of the Relevant Options.
(2) The stock options have vested and have become fully exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.